Flemington, Vikki et al
"AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib." Molecular Cancer Therapeutics
20.2
(2021):
238-249.
Web. 06 Mar. 2021.
